Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | PF-08046032 |
| Synonyms | |
| Therapy Description |
PF-08046032 is an antibody-drug conjugate (ADC) comprising an antibody targeting CD25 linked to monomethyl auristatin E, which potentially results in Treg depletion in the tumor microenvironment and increased antitumor immune response (Journal for ImmunoTherapy of Cancer 2024;12). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| PF-08046032 | PF 08046032|PF08046032 | PF-08046032 is an antibody-drug conjugate (ADC) comprising an antibody targeting CD25 linked to monomethyl auristatin E, which potentially results in Treg depletion in the tumor microenvironment and increased antitumor immune response (Journal for ImmunoTherapy of Cancer 2024;12). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06870487 | Phase I | PF-08046032 PF-06801591 + PF-08046032 | A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers | Active, not recruiting | USA | ESP | 0 |